Centessa Q1 net loss $38M; initiates ORX750 Phase 1, cash runway into mid-2026

Centessa Pharmaceuticals plc

2024-Q1 EPS reported -$0.38

Net loss of $38.0M, improved from $50.7M in Q1 2023; R&D expense $22.7M vs $32.8M.
Cash, equivalents, and short-term investments $230.2M as of March 31, plus $107.2M net from April/May ADS offering.
Phase 1 first-in-human trial of ORX750 (narcolepsy) initiated; proof-of-concept data expected 2H 2024.
SerpinPC registrational PRESent-2 interim analysis planned for 2024; Part 1 data to be shared late 2024/early 2025.
LB101 (PD-L1xCD47) Phase 1/2a for solid tumors ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2024 results: net income $38.0 million.

Period: the first quarter ended March 31, 2024
Net income: $38.0 million
Result: reported results

Exact text from the filing

Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-24-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.